/
Other
Endometriosis
45
Pipeline Programs↗
59
Active Trials↗
40
Companies Involved↗
Endometriosis is a moderately active landscape with 45 programs across 40 companies. The most active players are Bio Meds Pharmaceutica Ltda, Kissei Pharmaceutical Co., Ltd., Changchun GeneScience Pharmaceutical Co., Ltd.. 10 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical30
Phase 12
Phase 23
Phase 310
Approved
No programs
Analysis
Modality Breakdown
98%
Small molecule
40 of 41 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 41 classified programs, each share of the total. Modality classified for 98% of 45 pipeline programs.
Analysis
Trial Status
250
clinical trials
Completed131 · 52%
Recruiting35 · 14%
Unknown status32 · 13%
Terminated18 · 7%
Not yet recruiting14 · 6%
Withdrawn10 · 4%
Other10 · 4%
Clinical Trials
Trial Activity
250 trials
Guangdong Provincial Endometriosis Clinical Research Cohort
Recruiting·—·N/A·NCT07749053·716 enrolled
PAIN-GP: Project Assessing the Mechanisms and Impact of a Novel Cannabinoid Product for Gynecologic Pain
Recruiting·—·Preclinical·NCT07728695·60 enrolled
Page 1 of 17
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)